Tabernanthalog

Tabernanthalog

Tabernanthalog is a synthetic analogue of the naturally occurring compound ibogaine. It was developed as part of a research program aimed at finding new treatments for drug addiction.

History

Tabernanthalog was first synthesized by a team of researchers led by David E. Olson at the University of California, Davis. The team was interested in the potential of ibogaine to treat drug addiction, but were concerned about its toxicity. They developed Tabernanthalog as a safer alternative.

Chemistry

Tabernanthalog is a synthetic analogue of ibogaine, which is a naturally occurring psychoactive compound found in a number of plants in the Apocynaceae family. It is structurally similar to ibogaine, but has been modified to reduce its toxicity.

Pharmacology

Like ibogaine, Tabernanthalog is believed to work by targeting the sigma-2 receptor, a protein that is involved in the regulation of cellular stress response and cell death. It is thought that by modulating the activity of this receptor, Tabernanthalog can help to reduce the cravings and withdrawal symptoms associated with drug addiction.

Clinical significance

Research into the potential of Tabernanthalog as a treatment for drug addiction is still in its early stages. However, preliminary studies have shown promising results. In animal models, Tabernanthalog has been found to reduce self-administration of methamphetamine, suggesting that it could be effective in treating addiction to this drug.

See also

• Ibogaine
• Sigma-2 receptor
• Drug addiction